Mary's Medicinals

In the cannabis market, Mary's Medicinals has shown consistent performance in various categories and states. For instance, in the California market, the brand has maintained a steady rank in the Capsules category, holding the 11th position from August to November 2023. The brand's Tincture & Sublingual products also held the 4th rank consistently in the same period. In the Topical category, Mary's Medicinals performed exceptionally well, securing the 2nd rank throughout the period. In contrast, the brand's performance in the Missouri market shows a significant improvement in the Capsules category, moving from an unranked position in August to the 7th rank by October.

However, the brand's performance shows some variability across different states. For instance, while Mary's Medicinals secured the top rank for Topical products in Missouri, it held the 8th rank in the same category in Ohio and Nevada. In the Tincture & Sublingual category, the brand's ranking improved in Nevada, moving from the 17th position to the 12th from August to November. However, in Maryland, the brand's ranking in the same category dropped from 1st to 4th. The brand was not in the top 20 in the Topical category in Washington until November when it secured the 16th rank.

In the California Topical category, Mary's Medicinals consistently maintains the second rank position from August to November 2023, indicating a strong presence in the market. However, it's worth noting that the brand's sales seem to plateau, with only minor fluctuations over the period. The leading brand in this category, Papa & Barkley, consistently outranks Mary's Medicinals, with sales figures significantly higher. On the other hand, brands like Buddies and Sweet ReLeaf (CA) trail behind Mary's Medicinals, securing the third and fourth positions respectively. While Buddies maintains its rank, Sweet ReLeaf (CA) slips to the fifth position in October, indicating a potential opportunity for Mary's Medicinals to widen its competitive gap. However, the consistent second rank position of Mary's Medicinals suggests a need for strategic initiatives to challenge the dominance of Papa & Barkley.

In November 2023, the top-performing product from Mary's Medicinals was the Indica Transdermal Patch (20mg) with sales reaching 7356 units. This product regained its first position after dropping to the second place in September and October. The Sativa Energy Transdermal Patch (20mg), which had topped the list in the previous two months, slipped to the second position with 7228 units sold. The third spot was held by the CBD/THC/CBN 2:3:1 Formula Transdermal Patch (10mg CBD, 15mg THC, 5mg CBN) with 6959 units sold, maintaining its position from the previous months. The CBD/THC 1:1 Transdermal Patch (10mg CBD, 10mg THC) and CBD/THC 1:1 Relief Transdermal Compound Balm (500mg CBD, 500mg THC, 1oz) occupied the fourth and fifth positions respectively.